| DC4132 |
CP-547632
Featured
|
CP-547632 is as a potent inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases (IC50 11 and 9 nM, respectively). |
|
| DC9265 |
CP-640186 hydrochloride
Featured
|
CP-640186 Hcl is an isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively; with improved metabolic stability vs CP-610431. |
|
| DC7975 |
CP 640186
Featured
|
CP-640186 is an isozyme-nonselective acetyl-CoA carboxylase inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. |
|
| DC11410 |
CP-671305
Featured
|
CP-671305 is a potent and selective inhibitor of phosphodiesterase 4. |
|
| DC8251 |
CP-724,714 |
CP-724,714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc. Phase 2. |
|
| DC8892 |
CP724714 |
CP-724714 is a potent, selective inhibitor of HER2/ErbB2 with IC50 of 10 nM, >640-fold selectivity against EGFR, InsR, IRG-1R, PDGFR, VEGFR2, Abl, Src, c-Met etc in cell-free assays. Phase 2. |
|
| DC9317 |
CP-809101 (hydrochloride) |
CP-809101 Hcl is a potent and selective 5-HT2C receptor agonist with pEC50 of 9.96/7.19/6.81 for human 5-HT2C/5-HT2B/5-HT2A receptors respectively. |
|
| DC9385 |
CPA inhibitor |
CPA inhibitor is a potent inhibitor for carboxypeptidase A (CPA). |
|
| DC23544 |
CPG-52364 |
CPG-52364 (CPG52364) is an orally available, small molecule TLR7/8/9 antagonist for the treatment of systemic lupus erythematosus and other autoimmune disorders.. |
|
| DC10506 |
CPHPC(Miridesap)
Featured
|
CPHPC(GSK2315698,Miridesap) is a divalent crosslinker of SAP that causes rapid depletion of circulating SAP via hepatic clearance. |
|
| DC7564 |
CPI 0610(Pelabresib)
Featured
|
CPI 0610 is a potent, selective, and cell-active BET bromodomain inhibitor with IC50 of 39 nM for BRD4-BD1 in TR-FRET assay. |
|
| DC9736 |
CPI1189(REN-1189)
Featured
|
CPI-1189 prevents apoptosis and reduces glial fibrillary acidic protein immunostaining in a TNF-alpha infusion model for AIDS dementia complex. |
|
| DC8001 |
CPI 169 R-enantiomer
Featured
|
CPI-169 R is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2. |
|
| DC8466 |
CPI-169 (racemate）
Featured
|
CPI-169 racemate is the racemate form of CPI-169, which is a novel and potent EZH2 inhibitor with IC50 <1 nM(inhibition of the catalytic activity of PRC2); decreases cellular levels of H3K27me3 with an EC50 of 70 nM, and triggers cell cycle arrest and apo |
|
| DC5046 |
CPI203 (CPI-203)
Featured
|
CPI203 is a novel potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 with an IC50 of ~37 nM (BRD4 α-screen assay). |
|
| DC8619 |
CPI-268456
Featured
|
CPI-268456 is a potential BET bromodomain inhibitor. |
|
| DC8002 |
CPI-360 (R)
Featured
|
CPI-360 is a compound in design and preparation of wew palladium precatalysts for C-C and C-N cross-coupling reactions. |
|
| DC10527 |
Ciforadenant (CPI-444)
Featured
|
CPI-444 is an orally administered antagonist of the adenosine A2A receptor. It is designed to block the action of adenosine that is produced by tumors. |
|
| DC10593 |
CPI-455 analogue(KDM5 inhibitor)
Featured
|
CPI-455 analogue is a selective inhibitor of KDM5 demethylases. |
|
| DC9858 |
CPI-455
Featured
|
CPI-455 is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents. |
|
| DC10591 |
CPI-613
Featured
|
CPI-613 is an E1α pyruvate dehydrogenase (PDH) modulator that prevents cancer cells from metabolizing glucose for energy. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer. |
|
| DC10477 |
CPI-637
Featured
|
CPI-637 is a potent and selective CBP/EP300 bromodomains inhibitor with IC50 of 0.03±0.01μM and 11.0±0.6 μM for CBP/EP300 and BRD4, respectively. |
|
| DC22874 |
CPI644 |
CPI644 is a potent, selective, cell-active CBP/EP300 bromodomain inhibitor with IC50 of 0.18 uM for CBP. |
|
| DC20925 |
CPP-115 |
CPP-115 is an orally available, small molecule, next-generation GABA aminotransferase (GABA-AT) inhibitor with Ki of 31 uM, without other GABAergic or off-target activities. |
|
| DC9508 |
CPPHA
Featured
|
CPPHA is a selective positive allosteric modulator of mGluR5 receptor. |
|
| DC10982 |
CPSI-1306 |
CPSI-1306 (CPSI1306) is an orally available small-molecule MIF antagonist, protects against UVB-induced squamous cell carcinoma, reduces the severity of animal model of multiple sclerosis.. |
|
| DC22061 |
CPT157633 |
CPT157633 is a novel potent, selective PTP1B inhibitor with Ki of 40 nM, shows markedly less activities against a panel of 6 PTPs and 2 dual-specificity phosphatases. |
|
| DC10970 |
CPTH2 |
CPTH2 is a specific histone acetyltransferase inhibitor modulating Gcn5 network in vitro and in vivo, inhibits H3 acetylation and induces cell-cycle perturbation and apoptosis in U-937 cells. |
|
| DC10969 |
CPTH6 hydrobromide |
CPTH6 hydrobromide is a thiazole derivative that can reduce histone acetylation and histone acetyltransferase (HAT) activity in human leukemia cells, CPTH6 is a specific Gcn5/pCAF inhibitor. |
|
| DC10968 |
CPTH6 |
CPTH6 is a thiazole derivative that can reduce histone acetylation and histone acetyltransferase (HAT) activity in human leukemia cells, CPTH6 is a specific Gcn5/pCAF inhibitor. |
|
